TFFP insider filings
TFF Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-07-08. Screen TFFP transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TFFP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — TFF Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-07-08 | 4 | COLEMAN KIRK ALLEN — Chief Financial Officer | Grant/award (A): 10,184 @ $0 · Grant/award (A): 10,184 (derivative) @ $0 | EDGAR |
| 2024-07-08 | 4 | Mikhak Zamaneh — Chief Medical Officer | Grant/award (A): 10,184 @ $0 · Grant/award (A): 10,184 (derivative) @ $0 | EDGAR |
| 2024-07-08 | 4 | Weisman Harlan F — President and CEO, Director | Grant/award (A): 27,480 @ $0 · Grant/award (A): 27,480 (derivative) @ $0 | EDGAR |
| 2024-07-08 | 4 | Lee Catherine Chai-zon — Director | Grant/award (A): 1,583 @ $0 · Grant/award (A): 1,583 (derivative) @ $0 | EDGAR |
| 2024-07-08 | 4 | Roberts Brandi — Director | Grant/award (A): 3,165 @ $0 · Grant/award (A): 3,165 (derivative) @ $0 | EDGAR |
| 2024-07-08 | 4 | KING THOMAS BRAXTON — Director | Grant/award (A): 1,583 @ $0 · Grant/award (A): 1,583 (derivative) @ $0 | EDGAR |
| 2024-07-08 | 4 | MILLS ROBERT S — Director | Grant/award (A): 3,165 @ $0 · Grant/award (A): 3,165 (derivative) @ $0 | EDGAR |
| 2024-07-08 | 4 | ROCAMBOLI STEPHEN — Director | Grant/award (A): 3,165 @ $0 · Grant/award (A): 3,165 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | Patane Michael A — Director | Grant/award (A): 3,556 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | COLEMAN KIRK ALLEN — Chief Financial Officer | Grant/award (A): 5,300 (derivative) @ $0 · Grant/award (A): 10,600 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | Mikhak Zamaneh — Chief Medical Officer | Grant/award (A): 5,300 (derivative) @ $0 · Grant/award (A): 10,600 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | Weisman Harlan F — President and CEO, Director | Grant/award (A): 44,967 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | Lee Catherine Chai-zon — Director | Grant/award (A): 3,556 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | Roberts Brandi — Director | Grant/award (A): 5,333 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | KING THOMAS BRAXTON — Director | Grant/award (A): 3,110 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | MILLS ROBERT S — Director | Grant/award (A): 4,667 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | ROCAMBOLI STEPHEN — Director | Grant/award (A): 4,667 (derivative) @ $0 | EDGAR |
| 2023-12-15 | 4 | KING THOMAS BRAXTON — Director | Grant/award (A): 132,442 (derivative) @ $0 | EDGAR |
| 2023-12-04 | 4 | Patane Michael A — Director | Grant/award (A): 132,442 (derivative) @ $0 | EDGAR |
| 2023-12-04 | 4 | Lee Catherine Chai-zon — Director | Grant/award (A): 132,442 (derivative) @ $0 | EDGAR |
| 2023-12-04 | 4 | Roberts Brandi — Director | Grant/award (A): 52,858 (derivative) @ $0 | EDGAR |
| 2023-12-04 | 4 | MILLS ROBERT S — Director | Grant/award (A): 52,858 (derivative) @ $0 | EDGAR |
| 2023-12-04 | 4 | ROCAMBOLI STEPHEN — Director | Grant/award (A): 52,858 (derivative) @ $0 | EDGAR |
| 2023-08-17 | 4 | CARLSON CAPITAL L P — 10% owner Double Black Diamond Offshore Ltd — 10% owner Asgard Investment Corp. II — 10% owner Carlson Clint Duane — 10% owner | Sale (S): 215,000 @ $0.44 · Sale (S): 1,000 @ $0.39 | EDGAR |
| 2023-08-15 | 4 | COLEMAN KIRK ALLEN — Chief Financial Officer | Purchase (P): 20,000 @ $0.25 | EDGAR |
| 2023-08-15 | 4 | Mikhak Zamaneh — Chief Medical Officer | Purchase (P): 120,000 @ $0.25 | EDGAR |
| 2023-08-15 | 4 | Weisman Harlan F — President and CEO, Director | Purchase (P): 600,000 @ $0.25 | EDGAR |
| 2023-08-15 | 4 | Roberts Brandi — Director | Purchase (P): 20,000 @ $0.25 | EDGAR |
| 2023-08-15 | 4 | MILLS ROBERT S — Director | Purchase (P): 40,000 @ $0.25 | EDGAR |
| 2023-08-15 | 4 | ROCAMBOLI STEPHEN — Director | Purchase (P): 20,000 @ $0.25 | EDGAR |
| 2023-03-24 | 4 | COLEMAN KIRK ALLEN — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-03-13 | 4 | COLEMAN KIRK ALLEN — Chief Financial Officer | Purchase (P): 12,000 @ $0.79 | EDGAR |
| 2023-03-13 | 4 | Mikhak Zamaneh — Chief Medical Officer | Purchase (P): 15,000 @ $0.82 | EDGAR |
| 2023-03-13 | 4 | Weisman Harlan F — President and CEO, Director | Purchase (P): 150,000 @ $0.88 | EDGAR |
| 2023-03-13 | 4 | ROCAMBOLI STEPHEN — Director | Purchase (P): 13,000 @ $0.80 | EDGAR |
| 2022-12-30 | 4 | Fletcher Aaron G.L. — Director | Grant/award (A): 33,475 (derivative) @ $0 | EDGAR |
| 2022-12-30 | 4 | Roberts Brandi — Director | Grant/award (A): 20,968 (derivative) @ $0 | EDGAR |
| 2022-12-30 | 4 | MILLS ROBERT S — Director | Grant/award (A): 33,475 (derivative) @ $0 | EDGAR |
| 2022-12-30 | 4 | ROCAMBOLI STEPHEN — Director | Grant/award (A): 33,475 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | Weisman Harlan F — President and CEO, Director | Purchase (P): 50,000 @ $1.06 | EDGAR |
| 2022-12-06 | 4 | Weisman Harlan F — President and CEO, Director | Grant/award (A): 1,792,450 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | Fletcher Aaron G.L. — Director | Purchase (P): 43,470 @ $1.15 · Purchase (P): 21,735 (derivative) @ $0 | EDGAR |
| 2022-09-30 | 4 | THURMAN RANDY H — Director | Option exercise (M): 40,255 @ $2.50 · Sale (S): 40,255 @ $4.29 · Option exercise (M): 40,255 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Weisman Harlan F — Director | Purchase (P): 2,500 @ $5.12 · Purchase (P): 4,615 @ $5.50 | EDGAR |
| 2022-05-17 | 4 | Fletcher Aaron G.L. — Director | Purchase (P): 85,000 @ $4.86 · Purchase (P): 24,600 @ $5.08 | EDGAR |
| 2022-05-17 | 4 | COLEMAN KIRK ALLEN — Chief Financial Officer | Purchase (P): 1,250 @ $4.40 · Purchase (P): 425 @ $4.83 | EDGAR |
| 2022-05-17 | 4 | Mattes Glenn R. — President and CEO, Director | Purchase (P): 16,000 @ $4.78 | EDGAR |
| 2022-05-17 | 4 | Weisman Harlan F — Director | Purchase (P): 2,500 @ $4.74 | EDGAR |
| 2022-05-17 | 4 | ROCAMBOLI STEPHEN — Director | Purchase (P): 3,000 @ $4.54 | EDGAR |
| 2022-04-04 | 4 | Fletcher Aaron G.L. — Director | Purchase (P): 500,000 @ $6.43 · Purchase (P): 42,000 @ $6.89 | EDGAR |
Recent 8-K events — TFF Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-03-06 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-02-03 | 8-K | 3.02 — Unregistered Sales of Equity Securities 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2024-12-10 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-11-14 | 8-K | 1.02 — Termination of a Material Definitive Agreement ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-06 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-06-07 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2024-05-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TFFP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs